126 related articles for article (PubMed ID: 8861786)
1. Trimedoxime and HI-6: kinetic comparison after intravenous administration to mice.
Milic B; Maksimovic M; Nedelijkovic M
Pharmacol Toxicol; 1996 Apr; 78(4):269-72. PubMed ID: 8861786
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
[TBL] [Abstract][Full Text] [Related]
3. Partition of bispyridinium oximes (trimedoxime and K074) administered in therapeutic doses into different parts of the rat brain.
Karasova JZ; Zemek F; Bajgar J; Vasatova M; Prochazka P; Novotny L; Kuca K
J Pharm Biomed Anal; 2011 Apr; 54(5):1082-7. PubMed ID: 21146949
[TBL] [Abstract][Full Text] [Related]
4. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration.
Lukey BJ; Woodard CL; Clark CR; McCluskey MP
J Pharm Pharmacol; 1992 Aug; 44(8):690-2. PubMed ID: 1359099
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice.
Kassa J; Karasova J; Musilek K; Kuca K
Toxicology; 2008 Jan; 243(3):311-6. PubMed ID: 18054821
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma.
Karasova JZ; Chladek J; Hroch M; Josef F; Hnidkova D; Kuca K
J Appl Toxicol; 2013 Jan; 33(1):18-23. PubMed ID: 21717485
[TBL] [Abstract][Full Text] [Related]
7. Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.
Zdarova Karasova J; Zemek F; Kunes M; Kvetina J; Chladek J; Jun D; Bures J; Tachecí I; Kuca K
Neuro Endocrinol Lett; 2013; 34 Suppl 2():74-8. PubMed ID: 24362096
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.
Spöhrer U; Thiermann H; Klimmek R; Eyer P
Arch Toxicol; 1994; 68(8):480-9. PubMed ID: 7802588
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia.
Clement JG; Lee MJ; Simons KJ; Briggs CJ
Biopharm Drug Dispos; 1990 Apr; 11(3):227-32. PubMed ID: 2328309
[TBL] [Abstract][Full Text] [Related]
11. Effect of poisoning by soman (pinacolyl methylphosphonofluoridate) on the serum half-life of the cholinesterase reactivator HI-6 in mice.
Clement JG; Simons KJ; Briggs CJ
Biopharm Drug Dispos; 1988; 9(2):177-86. PubMed ID: 3370306
[TBL] [Abstract][Full Text] [Related]
12. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.
Clement JG; Bailey DG; Madill HD; Tran LT; Spence JD
Biopharm Drug Dispos; 1995 Jul; 16(5):415-25. PubMed ID: 8527690
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of two new asymmetric bispyridinium oximes (K-27 and K-48) in rats exposed to diisopropylfluorophosphate: comparison with pralidoxime, obidoxime, trimedoxime, methoxime, and HI-6.
Lorke DE; Hasan MY; Nurulain SM; Kuca K; Schmitt A; Petroianu GA
Toxicol Mech Methods; 2009 May; 19(4):327-33. PubMed ID: 19778224
[TBL] [Abstract][Full Text] [Related]
14. HI-6 and 2-PAM in sheep: pharmacokinetics and effects on muscle tissue following intramuscular injection.
Moore DH; Hayward IJ; Tucker FS; Lukey B
Biopharm Drug Dispos; 1991 Apr; 12(3):223-32. PubMed ID: 2059672
[TBL] [Abstract][Full Text] [Related]
15. The benefit of combination of oximes for the neuroprotective efficacy of antidotal treatment of sarin-poisoned rats.
Kassa J; Kunesova G
Toxicol Mech Methods; 2012 May; 22(4):260-7. PubMed ID: 22149934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice.
Clement JG; Shiloff JD; Gennings C
Arch Toxicol; 1987; 61(1):70-5. PubMed ID: 3326546
[TBL] [Abstract][Full Text] [Related]
17. HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases.
Eyer P; Hagedorn I; Klimmek R; Lippstreu P; Löffler M; Oldiges H; Spöhrer U; Steidl I; Szinicz L; Worek F
Arch Toxicol; 1992; 66(9):603-21. PubMed ID: 1482283
[TBL] [Abstract][Full Text] [Related]
18. The benefit of combinations of oximes for the reactivating and therapeutic efficacy of antidotal treatment of sarin poisoning in rats and mice.
Kassa J; Karasova JZ; Sepsova V; Caisberger F
Basic Clin Pharmacol Toxicol; 2011 Jul; 109(1):30-4. PubMed ID: 21235715
[TBL] [Abstract][Full Text] [Related]
19. Tabun-inhibited rat tissue and blood cholinesterases and their reactivation with the combination of trimedoxime and HI-6 in vivo.
Bajgar J; Karasova JZ; Kassa J; Cabal J; Fusek J; Blaha V; Tesarova S
Chem Biol Interact; 2010 Sep; 187(1-3):287-90. PubMed ID: 20167212
[TBL] [Abstract][Full Text] [Related]
20. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs.
Maksimović M; Jovanović D; Kovacević V; Bokonjić D
Toxicol Lett; 1987 Nov; 39(1):85-91. PubMed ID: 3672559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
